Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045954306> ?p ?o ?g. }
- W3045954306 endingPage "69" @default.
- W3045954306 startingPage "58" @default.
- W3045954306 abstract "Purpose To investigate the association between cardiovascular disease and baseline structural defects and disease progression in glaucoma. Design Prospective, longitudinal study of preperimetric and perimetric glaucoma. Participants Two thousand six hundred twenty-eight eyes from 1314 participants recruited to the Progression Risk of Glaucoma: Relevant SNPs with Significant Association (PROGRESSA) study were evaluated for baseline and longitudinal structural thinning using spectral-domain OCT and for visual field progression on Humphrey visual field (HVF) assessment. Methods Patients were classified as either predominantly macula ganglion cell–inner plexiform layer (mGCIPL), predominantly peripapillary retinal nerve fiber layer (pRNFL), or both mGCIPL and pRNFL structural change at enrollment, and then evaluated for longitudinal OCT or HVF progression. Cardiovascular disease and medication characteristics of the participants were compared with a reference group of stable patients. Main Outcome Measures OCT and HVF baseline status and longitudinal progression. Results After accounting for age and cardiovascular characteristics, patients with predominantly mGCIPL thinning at baseline showed a higher prevalence of hypertension (odds ratio [OR], 2.70; 95% confidence interval [CI], 1.66–4.41; P < 0.001), antihypertensive use (OR, 2.03; 95% CI, 1.20–3.46; P = 0.008), and statin use (OR, 1.98; 95% CI, 1.07–3.66; P = 0.029) than reference patients. Patients with predominantly pRNFL thinning exhibited a comparable prevalence of cardiovascular disease or medication with reference patients. Review of longitudinal OCT and HVF data (mean follow-up, 5.34 ± 1.29 years) showed that hypertension was associated with an increased risk of both OCT (OR, 1.79; 95% CI, 1.17–2.75; P = 0.006) and HVF progression (OR, 1.92; 95% CI, 1.18–3.15; P = 0.013). A 1-standard deviation (approximately 21 mmHg) increase in systolic blood pressure at baseline was associated with a greater risk of OCT progression (OR, 1.27; 95% CI, 1.01–1.63; P = 0.041) and HVF progression (OR, 1.32; 95% CI, 1.01–1.73; P = 0.043). The association between systolic blood pressure and structural progression was comparable to that observed between intraocular pressure and structural progression (OR, 1.30; 95% CI, 1.01–1.67; P = 0.039). Conclusions Cardiovascular disease is an important risk factor for glaucoma progression. To investigate the association between cardiovascular disease and baseline structural defects and disease progression in glaucoma. Prospective, longitudinal study of preperimetric and perimetric glaucoma. Two thousand six hundred twenty-eight eyes from 1314 participants recruited to the Progression Risk of Glaucoma: Relevant SNPs with Significant Association (PROGRESSA) study were evaluated for baseline and longitudinal structural thinning using spectral-domain OCT and for visual field progression on Humphrey visual field (HVF) assessment. Patients were classified as either predominantly macula ganglion cell–inner plexiform layer (mGCIPL), predominantly peripapillary retinal nerve fiber layer (pRNFL), or both mGCIPL and pRNFL structural change at enrollment, and then evaluated for longitudinal OCT or HVF progression. Cardiovascular disease and medication characteristics of the participants were compared with a reference group of stable patients. OCT and HVF baseline status and longitudinal progression. After accounting for age and cardiovascular characteristics, patients with predominantly mGCIPL thinning at baseline showed a higher prevalence of hypertension (odds ratio [OR], 2.70; 95% confidence interval [CI], 1.66–4.41; P < 0.001), antihypertensive use (OR, 2.03; 95% CI, 1.20–3.46; P = 0.008), and statin use (OR, 1.98; 95% CI, 1.07–3.66; P = 0.029) than reference patients. Patients with predominantly pRNFL thinning exhibited a comparable prevalence of cardiovascular disease or medication with reference patients. Review of longitudinal OCT and HVF data (mean follow-up, 5.34 ± 1.29 years) showed that hypertension was associated with an increased risk of both OCT (OR, 1.79; 95% CI, 1.17–2.75; P = 0.006) and HVF progression (OR, 1.92; 95% CI, 1.18–3.15; P = 0.013). A 1-standard deviation (approximately 21 mmHg) increase in systolic blood pressure at baseline was associated with a greater risk of OCT progression (OR, 1.27; 95% CI, 1.01–1.63; P = 0.041) and HVF progression (OR, 1.32; 95% CI, 1.01–1.73; P = 0.043). The association between systolic blood pressure and structural progression was comparable to that observed between intraocular pressure and structural progression (OR, 1.30; 95% CI, 1.01–1.67; P = 0.039). Cardiovascular disease is an important risk factor for glaucoma progression." @default.
- W3045954306 created "2020-08-03" @default.
- W3045954306 creator A5005522131 @default.
- W3045954306 creator A5010178491 @default.
- W3045954306 creator A5012180713 @default.
- W3045954306 creator A5012599011 @default.
- W3045954306 creator A5012655700 @default.
- W3045954306 creator A5016581506 @default.
- W3045954306 creator A5017746535 @default.
- W3045954306 creator A5017819128 @default.
- W3045954306 creator A5027915808 @default.
- W3045954306 creator A5029948119 @default.
- W3045954306 creator A5037433676 @default.
- W3045954306 creator A5037639355 @default.
- W3045954306 creator A5039731589 @default.
- W3045954306 creator A5041104671 @default.
- W3045954306 creator A5047701250 @default.
- W3045954306 creator A5051354401 @default.
- W3045954306 creator A5053943974 @default.
- W3045954306 creator A5073656496 @default.
- W3045954306 creator A5074017926 @default.
- W3045954306 creator A5086317817 @default.
- W3045954306 date "2021-01-01" @default.
- W3045954306 modified "2023-09-23" @default.
- W3045954306 title "Cardiovascular Disease Predicts Structural and Functional Progression in Early Glaucoma" @default.
- W3045954306 cites W100156460 @default.
- W3045954306 cites W1856328802 @default.
- W3045954306 cites W1965435711 @default.
- W3045954306 cites W1970036264 @default.
- W3045954306 cites W1976491437 @default.
- W3045954306 cites W1982145341 @default.
- W3045954306 cites W1984618569 @default.
- W3045954306 cites W1999908627 @default.
- W3045954306 cites W2018071295 @default.
- W3045954306 cites W2026191355 @default.
- W3045954306 cites W2026198583 @default.
- W3045954306 cites W2032872662 @default.
- W3045954306 cites W2036044828 @default.
- W3045954306 cites W2041941594 @default.
- W3045954306 cites W2053390620 @default.
- W3045954306 cites W2084955832 @default.
- W3045954306 cites W2092433290 @default.
- W3045954306 cites W2103271636 @default.
- W3045954306 cites W2131365674 @default.
- W3045954306 cites W2143189496 @default.
- W3045954306 cites W2156078833 @default.
- W3045954306 cites W2165584423 @default.
- W3045954306 cites W2254999921 @default.
- W3045954306 cites W2287452154 @default.
- W3045954306 cites W2345604857 @default.
- W3045954306 cites W2501232351 @default.
- W3045954306 cites W2557439420 @default.
- W3045954306 cites W2594764275 @default.
- W3045954306 cites W2596983421 @default.
- W3045954306 cites W2606221115 @default.
- W3045954306 cites W2617937013 @default.
- W3045954306 cites W2627019718 @default.
- W3045954306 cites W2755346552 @default.
- W3045954306 cites W2786181500 @default.
- W3045954306 cites W2790716032 @default.
- W3045954306 cites W2792048312 @default.
- W3045954306 cites W2808983097 @default.
- W3045954306 cites W2923176347 @default.
- W3045954306 cites W2923871122 @default.
- W3045954306 cites W2942534761 @default.
- W3045954306 cites W2943705187 @default.
- W3045954306 cites W2979889407 @default.
- W3045954306 cites W3000547714 @default.
- W3045954306 doi "https://doi.org/10.1016/j.ophtha.2020.06.067" @default.
- W3045954306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32730956" @default.
- W3045954306 hasPublicationYear "2021" @default.
- W3045954306 type Work @default.
- W3045954306 sameAs 3045954306 @default.
- W3045954306 citedByCount "19" @default.
- W3045954306 countsByYear W30459543062021 @default.
- W3045954306 countsByYear W30459543062022 @default.
- W3045954306 countsByYear W30459543062023 @default.
- W3045954306 crossrefType "journal-article" @default.
- W3045954306 hasAuthorship W3045954306A5005522131 @default.
- W3045954306 hasAuthorship W3045954306A5010178491 @default.
- W3045954306 hasAuthorship W3045954306A5012180713 @default.
- W3045954306 hasAuthorship W3045954306A5012599011 @default.
- W3045954306 hasAuthorship W3045954306A5012655700 @default.
- W3045954306 hasAuthorship W3045954306A5016581506 @default.
- W3045954306 hasAuthorship W3045954306A5017746535 @default.
- W3045954306 hasAuthorship W3045954306A5017819128 @default.
- W3045954306 hasAuthorship W3045954306A5027915808 @default.
- W3045954306 hasAuthorship W3045954306A5029948119 @default.
- W3045954306 hasAuthorship W3045954306A5037433676 @default.
- W3045954306 hasAuthorship W3045954306A5037639355 @default.
- W3045954306 hasAuthorship W3045954306A5039731589 @default.
- W3045954306 hasAuthorship W3045954306A5041104671 @default.
- W3045954306 hasAuthorship W3045954306A5047701250 @default.
- W3045954306 hasAuthorship W3045954306A5051354401 @default.
- W3045954306 hasAuthorship W3045954306A5053943974 @default.
- W3045954306 hasAuthorship W3045954306A5073656496 @default.
- W3045954306 hasAuthorship W3045954306A5074017926 @default.
- W3045954306 hasAuthorship W3045954306A5086317817 @default.